Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy

Adverum Biotechnologies (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the...

Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022

Adverum Biotechnologies (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced that...